|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.660 USD | -0.21% |
|
-.--% | +3.10% |
| Apr. 15 | Evotec Taps CureVac Executive as COO | MT |
| Jan. 06 | CureVac ends coverage after BioNTech acquisition |  |
Business description: CureVac
Number of employees: 904
Sales by Activity: CureVac
| Fiscal Period: December | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) |
|---|---|---|---|---|---|
Discovery and Development of Biotechnological Applications | 48.87M | 103M | 67.42M | 53.76M | 535M |
Geographical breakdown of sales: CureVac
| Fiscal Period: December | 2020 (EUR) | 2021 (EUR) | 2022 (EUR) | 2023 (EUR) | 2024 (EUR) |
|---|---|---|---|---|---|
Belgium | 8.81M | 74.3M | 62.26M | 47.13M | 520M |
Switzerland | 695K | 919K | 3.37M | 5.42M | 12.95M |
Netherlands | 2.63M | 1.77M | 1.79M | 1.2M | 2.38M |
Others | - | - | - | 8K | - |
Germany | 1.88M | 26M | - | - | - |
United States | 34.85M | - | - | - | - |
Executive Committee: CureVac
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 2023-03-27 | |
Myriam Mendila
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Malte Greune
COO | Chief Operating Officer | 61 | 2021-06-30 |
Composition of the Board of Directors: CureVac
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 2015-07-31 | |
Mathias Hothum
BRD | Director/Board Member | 58 | 2015-07-31 |
| Director/Board Member | 69 | 2022-06-21 | |
| Director/Board Member | 63 | 2022-06-21 | |
Michael Brosnan
BRD | Director/Board Member | 71 | 2023-06-18 |
Birgit Hofmann
BRD | Director/Board Member | 60 | 2024-06-23 |
Mehdi Shahidi
BRD | Director/Board Member | 60 | 2024-08-31 |
Company details: CureVac
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- CVAC Stock
- Company CureVac
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
